Skip to main content Accessibility help
×
Home

Clozapine v. chlorpromazine in treatment-naive, first-episode schizophrenia: 9-year outcomes of a randomised clinical trial

  • Ragy R. Girgis (a1), Michael R. Phillips (a2), Xiaodong Li (a1), Kejin Li (a3), Huiping Jiang (a1), Chengjing Wu (a3), Naihua Duan (a1), Yajuan Niu (a3) and Jeffrey A. Lieberman (a1)...

Abstract

Background

The differential effects of so-called ‘first- and second-generation’ antipsychotic medications, when given in the first episode, on the long-term outcome of schizophrenia remain to be elucidated.

Aims

We compared the 9-year outcomes of individuals initially randomised to clozapine or chlorpromazine.

Method

One-hundred and sixty individuals with treatment-naive, first-episode schizophrenia or schizophreniform disorder in a mental health centre in Beijing, China were randomised to clozapine or chlorpromazine treatment for up to 2 years, followed by up to an additional 7 years of naturalistic treatment. The primary outcome was remission status for individuals in each group.

Results

Individuals in both groups spent essentially equal amounts of time in each clinical state over the follow-up time period (remission, 78%; intermediate, 8%; relapse, 14%). There were no significant differences on other measures of illness severity. The clozapine group was more likely than the chlorpromazine group to remain on the medication to which they were originally assigned (26% v. 10%, P = 0.01). There were no significant differences between the two groups on other secondary efficacy outcomes.

Conclusions

These findings support the comparability in effectiveness between antipsychotic medications but with slightly greater tolerability of clozapine in the treatment of first-episode psychosis.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Clozapine v. chlorpromazine in treatment-naive, first-episode schizophrenia: 9-year outcomes of a randomised clinical trial
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Clozapine v. chlorpromazine in treatment-naive, first-episode schizophrenia: 9-year outcomes of a randomised clinical trial
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Clozapine v. chlorpromazine in treatment-naive, first-episode schizophrenia: 9-year outcomes of a randomised clinical trial
      Available formats
      ×

Copyright

Corresponding author

Jeffrey A. Lieberman, MD, College of Physicians and Surgeons, Columbia University, New York State Psychiatric Institute, 1051 Riverside Dr., Unit 4, New York, NY 10032, USA. Email: jlieberman@columbia.edu

Footnotes

Hide All

Aspects of this study have been presented at the 2009 Annual Meeting of the American Psychiatric Association (San Francisco, USA, 17 May), the 2009 Annual Meeting of the New York County District Branch of the American Psychiatric Association (New York, USA, 30 April) and the 11th Annual Symposium on Statistics in Psychiatry (Philadelphia, USA, 11 May 2009).

See editorials, pp. 266–268 and 269–271, this issue.

This work was supported by funds from the Novartis Pharmaceutical Company, which also supplied medications.

Declaration of interest

R.R.G. has received research support from Janssen and Lilly through APIRE and a travel stipend from Lilly, Forest, and Elsevier Science through the Society of Biological Psychiatry. N.D. has received research support from Pfizer. J.A.L. has received research grant support from Acadia, Allon, AstraZeneca, Bristol-Myers Squibb, Forest Labs, GlaxoSmithKline, Janssen, Merck, Organon, Pfizer, and Wyeth. He has acted as a consultant and an advisory board member for Astra-Zeneca, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, and Pfizer; has been a consultant for Cephalon, Johnson & Johnson and Novartis; an advisory board member for Bioline, Forest Labs, Lundbeck, Organon and Wyeth; and a DSMB member for Solvay. J.A.L. has received no direct financial compensation or salary support for participation in research, consulting, advisory board or DSMB activities. J.A.L. holds a patent from Repligen.

Footnotes

References

Hide All
1 McGlashan, TH, Johannessen, JO. Early detection and intervention with schizophrenia: rationale. Schizophr Bull 1996; 22: 201–22.
2 Wyatt, RJ. Neuroleptics and the natural course of schizophrenia. Schizophr Bull 1991; 17: 325–51.
3 Emsley, R, Oosthuizen, PP, Kidd, M, Koen, L, Niehaus, DJ, Turner, HJ. Remission in first-episode psychosis: predictor variables and symptom improvement patterns. J Clin Psychiatry 2006; 67: 1707–12.
4 Marshall, M, Lewis, S, Lockwood, A, Drake, R, Jones, P, Croudace, T. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch Gen Psychiatry 2005; 62: 975–83.
5 Perkins, D, Lieberman, J, Gu, H, Tohen, M, McEvoy, J, Green, A, et al. Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders. Br J Psychiatry 2004; 185: 1824.
6 Perkins, DO, Gu, H, Boteva, K, Lieberman, JA. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry 2005; 162: 1785–804.
7 Lieberman, JA, Tollefson, GD, Charles, C, Zipursky, R, Sharma, T, Kahn, RS, et al. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry 2005; 62: 361–70.
8 Lieberman, JA, Bymaster, FP, Meltzer, HY, Deutch, AY, Duncan, GE, Marx, CE, et al. Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection. Pharmacol Rev 2008; 60: 358403.
9 Crespo-Facorro, B, Perez-Iglesias, R, Ramirez-Bonilla, M, Martinez-Garcia, O, Llorca, J, Vazquez-Barquero, JL. A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis. J Clin Psychiatry 2006; 67: 1511–21.
10 Emsley, RA. Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Risperidone Working Group. Schizophr Bull 1999; 25: 721–9.
11 Moller, HJ, Riedel, M, Jager, M, Wickelmaier, F, Maier, W, Kuhn, KU, et al. Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia. Int J Neuropsychopharmacol 2008; 11: 985–97.
12 Lieberman, JA, Tollefson, G, Tohen, M, Green, AI, Gur, RE, Kahn, R, et al. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry 2003; 160: 1396–404.
13 Sanger, TM, Lieberman, JA, Tohen, M, Grundy, S, Beasley, C Jr, Tollefson, GD. Olanzapine versus haloperidol treatment in first-episode psychosis. Am J Psychiatry 1999; 156: 7987.
14 Gaebel, W, Riesbeck, M, Wolwer, W, Klimke, A, Eickhoff, M, von Wilmsdorff, M, et al. Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia. J Clin Psychiatry 2007; 68: 1763–74.
15 Schooler, N, Rabinowitz, J, Davidson, M, Emsley, R, Harvey, PD, Kopala, L, et al. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry 2005; 162: 947–53.
16 Green, AI, Lieberman, JA, Hamer, RM, Glick, ID, Gur, RE, Kahn, RS, et al. Olanzapine and haloperidol in first episode psychosis: two-year data. Schizophr Res 2006; 86: 234–43.
17 Kahn, RS, Fleischhacker, WW, Boter, H, Davidson, M, Vergouwe, Y, Keet, IP, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008; 371: 1085–97.
18 Lieberman, JA, Stroup, TS, McEvoy, JP, Swartz, MS, Rosenheck, RA, Perkins, DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209–23.
19 Jones, PB, Barnes, TR, Davies, L, Dunn, G, Lloyd, H, Hayhurst, KP, et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006; 63: 1079–87.
20 Kane, J, Honigfeld, G, Singer, J, Meltzer, H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789–96.
21 Sikich, L, Frazier, JA, McClellan, J, Findling, RL, Vitiello, B, Ritz, L, et al. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry 2008; 165: 1420–31.
22 Leucht, S, Corves, C, Arbter, D, Engel, RR, Li, C, Davis, JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009; 373: 3141.
23 Breier, A, Hamilton, SH. Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia. Biol Psychiatry 1999; 45: 403–11.
24 Tollefson, GD, Birkett, MA, Kiesler, GM, Wood, AJ. Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biol Psychiatry 2001; 49: 5263.
25 Lieberman, JA, Phillips, M, Gu, H, Stroup, S, Zhang, P, Kong, L, et al. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology 2003; 28: 9951003.
26 Phillips, MR, Xiong, W, Zhao, ZA. Issues Involved in the Use of Scales for the Assessment of Negative and Positive Symptoms in Psychotic Patients [in Chinese]. Hubei Science and Technology Publishing House, 1990.
27 First, MB, Spitzer, RL, Gibbon, M, Williams, JBW. Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version (SCID-CV). American Psychiatric Press, 1996.
28 Phillips, MR, Xiong, W, Wang, RW, Gao, YH, Wang, XQ, Zhang, NP. Reliability and validity of the Chinese versions of the Scales for Assessment of Positive and Negative Symptoms. Acta Psychiatr Scand 1991; 84: 364–70.
29 Guy, W. ECDEU Assessment Manual for Psychopharmacology. Revised DHEW Pub. (ADM). National Institute for Mental Health, 1976.
30 Jones, SH, Thornicroft, G, Coffey, M, Dunn, G. A brief mental health outcome scale – reliability and validity of the Global Assessment of Functioning (GAF). Br J Psychiatry 1995; 166: 654–9.
31 Simpson, GM, Angus, JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212: 11–9.
32 Simpson, GM, Lee, JH, Zoubok, B, Gardos, G. A rating scale for tardive dyskinesia. Psychopharmacology (Berl) 1979; 64: 171–9.
33 Little, RJA, Rubin, DB. Statistical Analysis with Missing Data. John Wiley & Sons, 2002.
34 Agid, O, Remington, G, Kapur, S, Arenovich, T, Zipursky, RB. Early use of clozapine for poorly responding first-episode psychosis. J Clin Psychopharmacol 2007; 27: 369–73.
35 Gitlin, M, Nuechterlein, K, Subotnik, KL, Ventura, J, Mintz, J, Fogelson, DL, et al. Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. Am J Psychiatry 2001; 158: 1835–42.
36 Robinson, D, Woerner, MG, Alvir, JM, Bilder, R, Goldman, R, Geisler, S, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999; 56: 241–7.
37 Szymanski, SR, Cannon, TD, Gallacher, F, Erwin, RJ, Gur, RE. Course of treatment response in first-episode and chronic schizophrenia. Am J Psychiatry 1996; 153: 519–25.
38 Lehman, AF, Lieberman, JA, Dixon, LB, McGlashan, TH, Miller, AL, Perkins, DO, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004; 161: 156.
39 Penn, DL, Waldheter, EJ, Perkins, DO, Mueser, KT, Lieberman, JA. Psychosocial treatment for first-episode psychosis: a research update. Am J Psychiatry 2005; 162: 2220–32.
40 Kane, JM. Tardive dyskinesia rates with atypical antipsychotics in adults: prevalence and incidence. J Clin Psychiatry 2004; 65 (suppl 9): 1620.
41 Alvir, JM, Lieberman, JA, Safferman, AZ, Schwimmer, JL, Schaaf, JA. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med 1993; 329: 162–7.
42 Allison, DB, Mentore, JL, Heo, M, Chandler, LP, Cappelleri, JC, Infante, MC, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686–96.
43 Newcomer, JW. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry. 2007; 68 (suppl 4): 813.

Related content

Powered by UNSILO
Type Description Title
PDF
Supplementary materials

Girgis et al. supplementary material
Supplementary Table S1-S2

 PDF (34 KB)
34 KB

Clozapine v. chlorpromazine in treatment-naive, first-episode schizophrenia: 9-year outcomes of a randomised clinical trial

  • Ragy R. Girgis (a1), Michael R. Phillips (a2), Xiaodong Li (a1), Kejin Li (a3), Huiping Jiang (a1), Chengjing Wu (a3), Naihua Duan (a1), Yajuan Niu (a3) and Jeffrey A. Lieberman (a1)...

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.